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Abstract: Research in resistant hypertension has again focused on autonomic nervous system 
denervation – 50 years after it had been stopped due to postural hypotension and availability of 
newer drugs. These (ganglionic blockers) drugs have all been similarly stopped, due to postural 
hypotension and yet newer antihypertensive agents. Recent demonstration of the feasibility of 
limited regional transcatheter sympathetic denervation has excited clinicians due to potential 
therapeutic implications. Standard use of ambulatory blood pressure recording equipment 
may alter our understanding of the diagnosis, potential treatment strategies, and health care 
outcomes – when faced with patients whose office blood pressure remains in the hypertensive 
range – while under treatment with three antihypertensive drugs at the highest tolerable doses, 
plus a diuretic. We review herein clinical relationships between autonomic function, resistant 
hypertension, current treatment strategies, and reflect upon the possibility of changes in our 
approach to resistant hypertension.
Keywords: resistant hypertension, renal sympathetic ablation, autonomic nervous system, 
ambulatory blood pressure monitoring, blood pressure control
Introduction
In the Paton Lecture for 2010, Murray Esler1 of the Baker IDI Heart and Diabetes 
Institute, Melbourne, Australia, reviewed work from the von Euler lab at the Karolinska 
Institute in Solna, Sweden, which identified norepinephrine as the neurotransmitter of 
sympathetic nerves,2 whose total body activity could be estimated by an assay from 
a 24-hour urine collection.3 Esler referred to anatomical studies of Thomas Willis, 
published in 1664, in which a detailed dissection of the sympathetic nervous system 
appeared.4 Esler also referred to studies from the Cannon Lab5 at Harvard Medical 
School that gave insight into control of blood pressure and blood glucose in cats, dogs, 
and other species by measurements before and after surgical resections of major sym-
pathetic ganglia above and below the diaphragm (Table 1). These observations would 
eventually have a role in proposed treatments for resistant hypertension.
Willis and Cannon would have been very attentive at the Starling Lecture for 
2000, delivered by Gerald DiBona, of the University of Iowa School of Medicine, 
who described renal effector innervation as a selective unmyelinated fiber within 
myelinated fibers, permitting coordination of information emanating from kidney/
heart with continuous reflexes moving through the brainstem.6
Studies by DiBona, Kopp, and Sawin focused on kidney function by means of 
fluorescent histochemical and electron microscopic methods,7 demonstrating nerve 
endings in proximity to glomerular, tubular, and vascular structures.8 Surgical renal International Journal of Nephrology and Renovascular Disease 2013:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
150
D’elia and weinrauch
denervation interfered with conservation of sodium during 
low-salt diet9 and with excretion of sodium during infusion 
of normal saline.10 In further studies, Osborn, Thames, Sawin, 
and DiBona used micropuncture techniques, along with nerve 
stimulation/denervation, to locate a sodium-exchange site 
between the end of the proximal tubule and the beginning 
of the distal tubule, ie, the loop of Henle, and to demonstrate 
direct neurological control of this function.11 A secondary 
finding was sodium exchange in the distal tubule as a result 
of neurostimulation of the juxtaglomerular apparatus with 
activation of the renin–angiotensin–aldosterone system 
(Table 2).12
Observations on the relationship 
between autonomic control and 
resistant hypertension (Table 3)
with respect to heredity
There is evidence for inherited enhanced sympathetic activ-
ity in essential hypertensive families,13 as well as in fami-
lies with diabetes in pregnancy.14 Normotensive offspring 
of hypertensive parents have increased activation of the 
sympathetic nervous system in response to mental stress.13 
A general mechanism for essential hypertension involves 
accelerated turnover of norepinephrine in the midbrain 
and medulla.15 An animal model demonstrated that male 
offspring of diabetic mothers have greater enhancement of 
renal sympathetic activity.
with respect to  
type 1 diabetes
There are significant differences between type 1 diabetic 
patients (insulin sensitive) and type 2 diabetic patients (insulin 
resistant) with respect to the preponderance of parasympathetic 
dysfunction. In lean hypertensive type 1 nephropathy patients, 
preservation of estimated glomerular filtration rate through 
control of blood pressure with angiotensin-converting-enzyme 
(ACE) inhibition and control of blood glucose with intensive 
insulin protocols, has been demonstrated.16 In this popula-
tion, there was a high incidence of loss of parasympathetic 
function.17 Loss of parasympathetic function was associated 
with higher levels of blood pressure and more rapid rise in 
serum creatinine.18 When baseline impairment of cardiac auto-
nomic function was considered to be severe or advanced, there 
was no improvement during intensive blood pressure/blood 
glucose treatment for 6–18 months. However, improvement in 
parasympathetic function was found if baseline impairment of 
cardiac autonomic function was not severe or advanced.19 In 
addition, reduction in left ventricular mass was notable among 
patients with improved glycemia control.20 The simultaneous 
improvement in cardiac autonomic function and left ventricular 
mass may have more than coincidental implications, since 
Table 1 Brief history of the physiology of the autonomic nervous 
system
Dissection Century Relevant to physiology of organ systems
Neuro Cardiovascular Renal Hepatic
Total
  willis4 17th +
Macro
  Cannon5 20th + +
  Smithwick47 20th + +
  Parmley35 20th + +
Mini
  von euler2 20th +
Micro
  DiBona6 21st + +
  esler1 21st + +
Table 2   Impact  of  autonomic  nerve  innervation  on  renal 
physiology
Norepinephrine constricts glomerular efferent arteriole
Decreased renal blood flow stimulates renin-angiotensin-aldosterone 
Retains sodium in distal tubule
Activates sodium/potassium adenine triphosphatase in thick ascending 
limb of proximal tubule (loop of Henle) to increase interstitial osmolality 
promoting antidiuresis at collecting duct 
epinephrine increases expression of renin
erythropoietin secreted by peritubular interstitial cells derive from a 
neural cell line that respond to hypoxia53
Table 3 Mechanisms of resistant hypertension
Secondary forms of hypertension
  Renal artery stenosis
  Adrenal adenoma/hyperplasia
  Pheochromocytoma
Primary = essential hypertension = hyperactivity of the sympathetic 
nervous system
Inherited
    Hyperactivity of the sympathetic system without a decrease in the 
parasympathetic system
    Salt-sensitivity in African-Americans susceptible to focal 
glomerulosclerosis
Acquired
    Sympathetic hyperactivity with a decrease in parasympathetic function 
in diabetic nephropathy
    Excess white adipose tissue associated with sleep apnea-induced 
hypoxia
    Activation of inflammation + oxidative stress = .stimulation of 
sympathetic system
    Activation of cortical pathways to basal ganglia and brainstem by repeated 
episodes of hypoglycemia in type 1 diabetes
    Acute/chronic glomerular or tubulointerstitial renal diseaseInternational Journal of Nephrology and Renovascular Disease 2013:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
151
Autonomic nervous system and resistant hypertension
renal function was stabilized in the process.21 With loss of 
parasympathetic stimulation, sympathetic stimulation predom-
inates in type 1 diabetic nephropathy patients; platelet adhesion 
and aggregation are highly activated with no improvement 
noted, despite optimal blood pressure and glycemia control 
over a period of 6–18 months.22 Given the high prevalence of 
microvascular and parasympathetic dysfunction in our type 1 
diabetic population, it is understandable that researchers in the 
field of resistant hypertension would avoid this group for initial 
studies. But, in an attempt to promote parasympathetic stimu-
lation, investigators at the University of Mississippi Medical 
Center have been working with carotid sinus stimulation in 
human studies, demonstrating lower blood pressures and – in 
animal studies – showing decreased plasma norepinephrine 
concentration,23 which might have been anticipated to be 
helpful based upon earlier studies by Eckberg, Drabinsky, 
and Braunwald.24
with respect to type 2 diabetes, obesity, 
and other insulin-resistant states
Studies of obese animals demonstrate resistance to leptin 
binding to midbrain satiety centers. Resistance to usual 
concentrations of leptin results in higher secretion rates 
from white adipose tissue. As midbrain autonomic centers 
close to satiety centers are activated, an increase in rate and 
amplitude of sympathetic nerve discharge is noted.25 A local-
ized renin–angiotensin system has been described in white 
adipose tissue.26 Triglyceride stores in white adipose fat cells 
are susceptible to lysis by epinephrine with release of free 
fatty acids.27 The adipocyte is associated with an oxidation 
product (epoxy-keto derivative) of linoleic acid, which can 
be released to stimulate adrenal aldosterone secretion.28 
White adipose secretion may also secrete specific adrenal 
mineralocorticoid releasing factors.29 Vasoconstriction is 
partially ameliorated by white perivascular fat. But, in obe-
sity, this protective effect appears to be lost30 in association 
with altered mechanisms of inflammation and oxidative stress 
within the community of adipose cells.
Recent work by Yamada-Goto et al comes closer to an 
understanding of how an injection of leptin or associated 
compounds into the midbrain can stimulate the rate and 
amplitude of sympathetic nerve pulsation.31 These inves-
tigators have been using compounds (including serotonin, 
natriuretic peptide C, and other pharmaceutical agents) to 
find a way of activating the leptin-resistant midbrain receptor 
as a treatment for obesity.31 Clinical studies have, thus far, 
been thwarted by concerns raised by progressive elevations 
of blood pressure.
The possibility of activation of brain stem sympathetic 
centers from higher centers in the frontal or parietal cortex 
is another contribution to the list of mechanisms of resistant 
hypertension. In a series of studies from Harvard Medical 
School, Bolo et al32 found areas of higher centers activated 
by the thought process as in the working-memory task. 
The investigators used a magnetic resonance imaging tech-
nique, known as the blood oxygen level-dependent function 
(BOLD) MRI. When blood glucose was in the normal range, 
there were no differences between type 1 diabetic patients 
and normal controls. But when blood glucose levels were 
slowly decreased through controlled infusion of insulin 
(hyperinsulinemic clamp), it was possible to identify a 
unique network involving thalamus, hypothalamus, and 
brain stem, expressing an increased functional connectivity 
with basal ganglia only in the type 1 diabetic individuals.31 
Cognitive function (including memory) was retained at full 
capacity in the type 1 diabetic study subjects compared to 
normal controls. However, the diabetic group was relatively 
inefficient in brain oxygen utilization required to achieve 
full capacity in thinking. Inefficiency was visualized as the 
need both to exceed usual levels of intensity in brain areas 
undergoing activation as well as the inability to come to 
complete rest in areas undergoing a deactivation cycle. Some 
data exist indicating these differences occur in older type 2 
diabetic patients whose ability to perform working-memory 
tasks at full capacity may eventually diminish to a greater 
or lesser degree. In terms of intermittent hypoglycemia as 
a challenge to brain activation resources, there is now visu-
alization of pathways that activate brainstem centers that 
activate release of epinephrine. Then, if a cortical circuit 
is not able to recover completely from an initial signal of 
hypoglycemia before a subsequent episode of low blood 
glucose emerges, there is a kind of latency gridlock in which 
the individual may not be fully aware of the hypoglycemia, 
which is driving a reflex that pulsates at rapid rate with 
increased amplitude. Latency gridlock may interfere with 
awareness, but not with the brain’s demand for fuel. An 
extreme example of this may be seen when catechol-induced 
malignant hypertension of pheochromocytoma leads to sym-
pathetic/parasympathetic imbalance that proceeds, despite 
hyperglycemia when a beta-blocker is introduced without 
concomitant alpha blockade.
Sommers et al of Boston University Medical Center 
listed pheochromocytoma of the adrenal gland as the most 
important secondary cause of hypertension.33 This tumor may 
arise from the autonomic nervous system as it is related to 
paraganglioma cells that secrete catecholamines. A prolonged International Journal of Nephrology and Renovascular Disease 2013:6 submit your manuscript | www.dovepress.com
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release of epinephrine may increase renal expression of 
erythropoietin.
with respect to heart failure
DiBona and Sawin studied an experimental model of conges-
tive heart failure in the rat.34 They found control of cardiac 
pressure/volume relationships to be distorted with blunting 
of sympathetic activity that led to decreased renal perfusion 
with retention of fluid.
Blockade of the beta-adrenergic receptor preventing 
arrhythmia in ventricular muscle of the cat was the subject 
of experiments performed within the Cardiology Branch of 
the National Heart, Lung and Blood Institute (Bethesda, MD, 
USA). Using a blocker of systemic beta  -adrenergic receptors 
(DL-propranolol), Parmley and Braunwald found protection 
from arrhythmia.35,36 Vogel et al used a model of heart fail-
ure in calves surviving in Denver, CO, USA, at 5,280 feet, 
having undergone ligation of the pulmonary artery. As heart 
failure emerged, evidence of loss of norepinephrine secreting 
nerves was documented. When the animals were returned to 
sea-level air pressure, there was a reversal of heart failure 
associated with regrowth of adrenergic nerves.37,38
The importance of sympathetic neurostimulation in 
  congestive heart failure was elucidated by Gaffney and 
  Braunwald who used the ganglionic blocking agent, guanethi-
dine, in both early (Stage II) and advanced (Stages III, IV) 
congestive heart failure (CHF). The drug was tolerated in 
early-stage CHF patients, but not in the advanced stage 
patients.39 Francis et al of the Cardiovascular Division of 
the University of Minnesota Medical School measured 
plasma catecholamine of healthy subjects versus individu-
als under treatment for CHF. They found that to compete 
for equivalent amounts of low intensity exercise, the CHF 
group had to generate larger amounts of norepinephrine 
than healthy   subjects.40 Largely based upon the observation 
of   Swedberg et al and Waagstein et al in Göteborg, Sweden, 
in the 1970s,41,42 trials of beta blockade (metoprolol, carve-
dilol, bucindolol, and bisoprolol) in the 1980s and 1990s in 
Class III or Class IV heart failure have demonstrated ben-
efits in functional capacity, ejection fraction, and morbidity/
mortality. Severe heart failure is associated with elevated 
levels of norepinephrine, indicating hyperstimulation by the 
sympathetic nervous system ameliorated by beta-blockade.
A complicating feature of heart failure associated with 
obesity and often type 2 diabetes is obstructive sleep apnea. In 
obstructive sleep apnea, pathologic changes in cardiac pres-
sure/volume relationships during hypoxemia are associated 
with increased sympathetic input to the kidney with potential 
pathologic consequence over time. When obstructive sleep 
apnea or heart failure43 result from morbid obesity, increased 
sympathetic outflow from the brain stem is activated from 
within the adipose tissue itself.44
with respect to pregnancy
Since peripheral autonomic activity is often heightened in 
hypertensive women with obesity and diabetes mellitus, the 
additional stress of pregnancy may be inadvisable. When 
these risk factors are combined with hypoxia in the placenta, 
an excess of autonomic outflow causes resistant hyperten-
sion in association with a unique renal glomerular vascular 
pathology.45 Placental hypoxia during eclampsia appears to 
result from inhibition of the receptor for the vascular endothe-
lial growth factor responsible for adequate perfusion of the 
rapidly growing intensely metabolic organ.46 At a time when 
there were limited pharmacological choices, Newell and 
Smithwick47 at the Boston University School of   Medicine, 
used extensive surgical resection of autonomic nerves to 
prevent arterial vasoconstriction to the heart, kidney, and 
placenta by disrupting pathologically intensive reflex activity 
in women with resistant hypertension.
These observations were precursors to the work of 
  Harington, Kincaid-Smith, and McMichael,48 who used early 
ganglionic blocking agents to successfully treat malignant 
hypertension over a 7-year period. Irreversible postural 
hypotension was severe enough to contraindicate the Smith-
wick procedure when further antihypertensive agents became 
available.
Review of attempts to interrupt  
or suppress the deleterious effects 
of sympathetic autonomic nervous 
stimulation
From 1926–1929, the Physiology Laboratory of Walter B 
Cannon,5 working with cats, observed erection of dorsal hair 
as an endpoint for intact sympathetic innervation, with loss 
of erection as a sign of successful surgical interruption of 
the circuit. The procedure involved removal of sympathetic 
ganglia from the superior cervical ganglion to the pelvic brim. 
If the procedure were performed on the right side, then there 
would be hair erection only on the left if the animal were 
to enter the cold room. Other than the change in dorsal hair 
movement, the general impression was that of a normal labo-
ratory cat. In subsequent operations, an approach through a 
lower rib space allowed for removal of sympathetic nerves 
below the diaphragm.International Journal of Nephrology and Renovascular Disease 2013:6 submit your manuscript | www.dovepress.com
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Measurement of blood pressure demonstrated blockade 
of the usual hypertensive response to stress or excitement, 
fulfilling the hypothesis that blood vessel muscles were under 
control of the nervous system. They also found that shivering 
in the cold had been eliminated. Other usual responses to 
stress were a rise in blood glucose and an increase in red 
blood cell count. Both of these responses were blocked by 
the sympathectomy. The ratio of carbon dioxide exhaled 
to oxygen inhaled (respiratory quotient) at the time used to 
estimate total body basal metabolic rate did not change.
The next inquiry was to determine whether kidneys 
activate sympathetic nerves leading to hypertension, or if 
activation of sympathetic nerves cause vasoconstriction with 
injury to renal vessels, or both. Benjamin Castleman, patholo-
gist from the Massachusetts General Hospital, and Reginald 
Smithwick, thoracic surgeon from Boston   University, did 
extensive studies of renal biopsy and nephrectomy speci-
mens to determine if hypertension was of renal origin or if 
hypertension of extrarenal cause did injury to kidneys. In 
500 instances, they were able to classify the renovascular 
pathology of hypertensive patients. They found 68% of speci-
mens demonstrated grade II to III vascular pathology. Thus, 
32% had low-grade changes or no vascular pathology. They 
concluded the kidney was the source of high blood pressure, 
which might occur long before the onset of vascular injury.49 
But Smithwick might also have concluded that some portion 
of the resistant state of high blood pressure had originated 
above the level of the cardiorenal axis capable of being dis-
armed by the procedures that he and Cannon had performed. 
DiBona and Esler, 60 to 80 years later, could state that renal 
denervation surgery in hypertensive animals with increased 
sympathetic nerve activity resulted in diminished release of 
epinephrine from the denervated kidney.50 So, the stage was 
set at Boston City Hospital for extensive surgical intervention 
to bring down blood pressures that were not responsive to 
medication. Since the Smithwick procedure was destructive 
of lower thoracic and upper abdominal ganglia, there was a 
clinically significant degree of postural hypotension. But, 
since it prevented eclampsia in young women,46 it serves as 
a challenge for current age technologies, which are not likely 
to cause postural hypertension, anhydrosis, constipation, or 
male sexual dysfunction.
A relevant experimental model of renal denervation in the 
Dahl salt-sensitive hypertensive rat was used by Nagasu et al51 
at Kawasaki Medical School to demonstrate preservation of 
glomerular structures that would usually undergo fibrosis 
since this animal is highly susceptible to salt in the diet. 
A cellular mechanism for renal glomerular fibrosis was an 
oxidative stress reaction, secondary to excess activity of the 
oxidase of nicotinamide adenine dinucleotide phosphate 
(NADPH). The investigators point to research indicating 
that reactive oxygen species have been shown to enhance 
sympathetic nervous system activity. Salt-sensitive hyper-
tension models (Table 4) are needed in studies of African-
American groups prone to glomerulosclerosis.52 Glomerular 
and tubular diseases often have associated interstitial fibrosis, 
which determines the duration of useful kidney function. 
In an animal model of ureteral obstruction, followed by the 
generation of reactive oxygen species with development of 
interstitial fibrosis, Kim and Padamilam found renal dener-
vation to be protective from oxidative stress and interstitial 
fibrosis in this setting.53
While radiofrequency stimulation of the carotid body 
increases sympathetic nerve activity, stimulation at the peri-
carotid sinus area activates a parasympathetic signal without 
injury to the nerve. Experiments in dogs from the laboratory 
of Lohmeier and Illescu at the University of Mississippi 
Medical Center, found carotid sinus stimulation lowered 
blood pressure while decreasing plasma norepinephrine, 
suggesting that both a stimulation of parasympathetic and 
an inhibition of sympathetic activity had occurred.23 Further 
studies found neither a central nor a peripheral sympathetic 
reflex that could return blood pressure back to baseline. 
And, since there was no retention of sodium chloride, it was 
reasoned there had been an inhibition of renin that requires 
epinephrine stimulation. So when angiotensin II was infused 
to bypass renin-inhibition, then an aldosterone-related salt 
retention was able to restore blood pressure back to baseline 
Table 4   Resistant  hypertension  occurs  in  association  with  a 
number of factors
Resistant hypertension occurs in association with:
Acute/chronic glomerular or tubulointerstitial renal disease
Salt sensitivity, particularly if inherited with focal glomerulosclerosis
Individuals with a body mass index .30 kg/m2, particularly if:
  Over the age of 40 years
  Leading sedentary lives
  Demonstrating insulin resistance
  Susceptible to sleep apnea-induced hypoxia
  excreting increased levels of urine albumin/creatinine
Type 1 diabetic patients with Body Mass Index ,20 kg/m2
  Susceptible to repeated attacks of hypoglycemia
  Demonstrating loss of parasympathetic function
Chronic inflammation/oxidative stress, including repeated use of:
  Cigarettes
  Cocaine
  Pseudoephedrine, dextroamphetamine
  Ma huang herbal preparation
  Licorice root (Glycyrrhiza glabra)  aldosterone-like effectInternational Journal of Nephrology and Renovascular Disease 2013:6 submit your manuscript | www.dovepress.com
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through expansion of plasma volume. Since obesity-related 
hypertension involves enhanced sympathetic nerve activity 
with increased renin secretion, chronic stimulation of carotid 
sinus would be expected to improve blood pressure. A 2-year 
clinical trial of carotid sinus baroreflex activation has found 
significant diminution in systolic and diastolic pressure in 
patients with resistant hypertension54 without the troublesome 
side effect of postural hypotension that had been the down-
side of the Smithwick procedure.47 There are no follow-up 
studies on the combined use of radiofrequency ablation in 
the renal artery area plus radiofrequency stimulation of the 
carotid sinus area.
The mechanism of action of antihypertensive agents may 
impact on the autonomic nervous system. Differences are 
observed within pharmaceutical antihypertensive medica-
tion groups. The dihydropyridine calcium channel blocker 
nifedipine is associated with increased muscle sympathetic 
nerve activity and plasma norepinephrine as a reflex response 
to vasodilation and a fall in blood pressure (also seen with 
isosorbide and hydralazine). Nondihydropyridine calcium 
channel-blocking agents, however, are observed to decrease 
plasma norepinephrine (verapamil, diltizem); amlodipine had 
no impact on plasma norepinephrine.55 Among angiotensin-
converting enzyme inhibitors, which block the peripheral 
autonomic nervous system response to angiotensin 2, 
although use of captopril is associated with a fall of plasma 
norepinephrine and muscle sympathetic nerve activity, use 
of enalapril is not.56 Research has also revealed that use of 
clonidine, which acts to inhibit the central autonomic nervous 
system results in a fall of plasma norepinephrine and muscle 
sympathetic nerve activity.57
Definition and prevalence  
of resistant hypertension
Without the use of 24-hour ambulatory 
blood pressures
A 2011 review of data from participants in the National 
Health and Nutrition Surveys (NHANES) found 52.5% 
of individuals receiving no antihypertensive medication to 
have a blood pressure of 140/90 mmHg or higher. Among 
participants on antihypertensive medications, 28% were not 
in optimal control, and 12.8% were defined as resistant (blood 
pressure $140/90 mmHg despite $three antihypertensives) 
to medications.58 Prevalence of resistance however was 
reduced to 7.3%, if the requirement was for $four antihy-
pertensive medications.59 Thus, prevalence was largely defini-
tion based. The place of diuretic in the definition of resistant 
hypertension was not clear. Within the resistant-hypertension 
group, 85.6% were receiving a diuretic (hydrochlorothi-
azide, 64.4% of the time). Drugs inhibiting sympathetic 
nervous stimulation (Table 5), included beta-blocking agents 
(received by 75.5% of participants), alpha-adrenergic block-
ing agents (17.5%), and central acting adrenergic agents 
(10%).59 Chronic kidney disease, defined by estimated 
glomerular filtration rate #60 mL/minute or by spot check 
urine albumin level of $0.030 mg/mg creatinine was noted 
in 38% of participants. In 71% of participants, a greater 
than 20% risk for coronary events (Framingham score) 
was observed. The demographics of resistant hypertension 
include age .40 years, body mass index .30 kg/m2 with 
the presence of diabetes mellitus, chronic renal disease, and 
cardiovascular complications.
Important reflections by Calhoun et al,58 Alderman,60 and 
Egan et al61 have sought to clarify the definition of resistant 
hypertension. There is no universal consensus regarding 
documentation of compliance inclusion/exclusion of cer-
tain medication groups, which might be seen as first-line 
medication choices. There is no concern regarding the need 
to document exclusion of drugs like dextroamphetamine, 
pseudoephedrine, and nonsteroidal analgesics – some of 
which are available without prescription.
An additional issue that requires resolution is physi-
cians’ reluctance to resort to spironolactone or eplerenone 
before declaring resistance of hypertension to medications. 
The reluctance to use spironolactone in males is based on risk 
Table 5 Classification of hypertension control
From office setting
Greater than 130/80, but less than 140/90 on a diuretic, plus a number 
of antihypertensive medications
  One (mild)
  Two (moderate)
  Three (severe)
Greater than 140/90 on a diuretic plus three antihypertensive agents
    without papilledema or rapid loss of renal function  resistant 
hypertension
    with papilledema or rapid loss of renal function  malignant 
hypertension
Greater than 140/90 on no antihypertensive, but less than 140/90
  If taken outside of the office setting  white coat hypertension
Less than 140/90 on no antihypertensive, but greater than 140/90
  If taken outside of the office setting  masked hypertension
From 24-hour ambulatory recording on diuretic, plus three 
antihypertensives
Greater than 140/90 both day and night  resistant hypertension
Greater than 140/90 during day, less at night  pseudoresistant 
hypertension
Less than 140/90 during day, greater at night  persistent hypertensionInternational Journal of Nephrology and Renovascular Disease 2013:6 submit your manuscript | www.dovepress.com
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of growth of breast tissue; the high cost of eplerenone is also 
a hindrance. The obese salt-sensitive rat (SHR/CP) was used 
to elucidate the mechanism of salt-induced hypertension as 
an experimental metabolic syndrome model. After a period 
of salt loading, the level of aldosterone was appropriately 
decreased, associated with development of kidney injury 
and proteinuria. Despite the decrease in serum aldosterone, 
there was a paradoxical nuclear activation of the miner-
alocorticoid receptor, along with enhanced expression of 
aldosterone effector kinase in the kidney. Renal pathology 
included glomerular sclerosis, tubulointerstitial scarring, 
and depletion of nephrin from glomerular podocytes. Use 
of eplerenone by Nagase et al at Tokyo Graduate School of 
Medicine prevented the development of hypertension and 
this renal pathology.62
With the use of 24-hour blood pressure 
monitoring
Use of the 24-hour ambulatory blood pressure apparatus 
proves instructive in allocation of patients with resistant 
hypertension to effective treatment (Table 6). An individual 
receiving no antihypertensive medications whose blood 
pressure is above 140/90 mmHg in the office, but below 
140/90 mmHg in outside settings, is referred to as having 
“white coat hypertension,” but is referred to as “pseu-
doresistant hypertension,” if receiving an antihypertensive 
medication. This group should be considered at risk for 
unnecessary medication side effects, which might include 
loss of energy, postural hypotension, mental dullness, and 
emotional   depression. If failure to utilize 24-hour ambula-
tory blood pressure information is based on the lack of 
resources provided by insurance carriers, then there is a 
need to point out just how much money is being wasted 
on expensive medication. In an important study by de la 
Sierra et al,63 40% of individuals under treatment for resis-
tant hypertension could be reclassified to pseudo resistant 
by the finding of lower pressures overnight. An important 
subsequent study by De Nicola et al64 demonstrates that 
among patients with chronic renal disease reclassification 
from resistant hypertension to pseudoresistant by ambulatory 
blood pressure monitoring identified a subgroup with fewer 
cardiac and renal endpoints (Table 6). An ambulatory blood 
pressure study similar to that from Spain63 and Italy64 has 
been published from several centers in Japan. Iimuro et al65 
classified types of hypertension in chronic renal disease. 
A 26% incidence of persistent hypertension was reported 
(22%, 27%, and 36% if the estimated glomerular filtration 
rates were 30–45, 15–30, and ,15 mL/min, respectively). 
The incidence of drug resistant hypertension could not be 
determined precisely from the tables, but since only 26% 
of persistent hypertension patients received either diuretics 
or antihypertensives, on average, a maximum of 7% could 
have been drug resistant.
When an individual receiving no medication for high blood 
pressure has an office reading of less than 140/90 mmHg, but 
readings greater than 140/90 mmHg in outside settings, then 
this is usually referred to as “masked hypertension,” as it car-
ries with it an increased risk of cardiac and renal pathology 
(compared to the normotensive individual). For the individual 
already taking medication to control high blood pressure this 
pattern would more appropriately be labeled “persistent” 
hypertension. In the study by de la Sierra et al, as many as 
31% of individuals classified as “hypertension controlled 
by treatment” were reclassified as “persistent hypertension,” 
due to the finding of higher pressures overnight.63 It was not 
unexpected that this group had left ventricular hypertrophy 
with progressive loss of estimated glomerular filtration rate. 
Failure to utilize such 24-hour ambulatory blood pressure 
data may lead to premature use of end-stage renal disease 
(ESRD) resources.66
Measurement of effectiveness  
of blood pressure control
While effectiveness of antihypertensive procedures and 
medications has traditionally been reported on the basis of 
mmHg of blood pressure lowering, large-scale trials have 
recently focused on soft and hard endpoints.67 Analysis of 
hard endpoints in multiple trials has led to discontinuation 
Table 6 Consequences of being labeled with the diagnosis of 
chronic resistant hypertension and reclassification by the use of 
ambulatory blood pressure monitoring observed in a high-risk 
group (chronic renal disease)
Elevated office  
blood pressure
Controlled office 
blood pressure
elevated  
ambulatory  
blood pressure
True resistant  
25% 
Cv events: +++ 
Renal events: ++++ 
Consider discontinuation of 
ineffective medications, change 
medications, enroll in a trial
Sustained  
40% 
Cv events: ++ 
Renal events: +++ 
Increase in 
appropriate therapy 
to reduce risk
Controlled 
ambulatory  
blood pressure
Pseudoresistant  
10% 
Cv events: ++ 
Renal event: + 
Consider whether any problems 
result from overtreatment
Controlled  
25% 
Cv events: ++ 
Renal events: +
Abbreviation: Cv, cardiovascular; +, number of events.International Journal of Nephrology and Renovascular Disease 2013:6 submit your manuscript | www.dovepress.com
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of some drugs that initially looked promising with respect 
to surrogate endpoints (eg, flosequinan, rofecoxib). There 
remains a need for short-term trials of such biologic markers 
as changes in systolic and diastolic blood pressures, left ven-
tricular wall thickness, etc. However, longer-term trials must 
determine whether endpoints, such as all cause and cardiac 
mortality, cardiovascular events (eg, hospitalization for heart 
failure, myocardial infarction, coronary intervention, stroke, 
nontraumatic amputation), ESRD requiring renal replace-
ment therapy (dialysis, filtration, transplant), or blindness,63 
are favorably impacted.
Measurement of office blood pressure, though standard and 
well-established, is often misleading. Its use to define resistant 
hypertension has been supplanted by availability of devices that 
permit 24-hour blood pressure monitoring. Although use of 
such devices is required to demonstrate adequacy and duration 
of the blood pressure-lowering effect in trials of medications, 
they are not often clinically used. Refinement of the defini-
tion of resistant hypertension, and ultimately improvement in 
the effective monitoring of blood pressure by these devices is 
possible,62–64 with the use of ambulatory monitoring.
Based upon outcome studies, we believe it most appro-
priate to define blood pressure control under the following 
categories: normotensive, untreated office or “white coat” 
hypertension, untreated masked hypertension, controlled 
hypertension, pseudoresistant hypertension, sustained hyper-
tension, and resistant hypertension. Fortunately, properly 
defined, the latter category represents only a small proportion 
of the hypertensive population. Few reasons exist to avoid 
using diuretics in hypertensive patients, and thiazides must 
be supplemented or replaced by spironolactone, eplerenone, 
or loop diuretics as kidney and heart function deteriorate. 
Patients should not be considered resistant unless exposed 
to optimal timing and dosage of agents from each of the 
six following classes: (1) diuretic; (2) ACE (angiotensin 
converting enzyme inhibitor)/ARB (angiotensin receptor 
blocker)/DRI (direct renin inhibitor); (3) beta-blockade; 
(4)   calcium-channel blockade; (5) ganglionic blocking 
agents/Alpha 2 agonists; and (6) vasodilator.
Hypertension should also not be considered resistant 
to control in the presence of inadequate compliance or 
comorbidities, such as glycohemoglobin greater than ten, 
recurrent hypoglycemic episodes, or systemic inflammatory 
syndromes. Documentation of absence of substances that 
contribute salt, calories, sympathetic stimulation (dextroam-
phetamine, pseudoephedrine, cocaine, ephedra/ma huang), 
licorice root (Glycyrrhiza glabra), or analgesia (nonsteroidal 
analgesics, herbal preparations) is required.
Proposed treatments and 
sympathetic control targets for 
control of resistant hypertension
Medications currently undergoing preclinical trials for anti-
hypertensive treatment are not presumed to have predominant 
sympathetic autonomic effects.68 At this point, drug-resistant 
hypertension is being studied by means of radiofrequency69 or 
cryoablation70 of nerves surrounding the renal arteries, test-
ing the hypothesis that interruption of pathological reflexes 
with relaxation of stiff vessels, plus excretion of excess salt, 
would forestall cardiovascular events by restoring homeo-
static relationships.
In 2012, Savard et al published criteria for use of renal 
denervation.71 The criteria included age .18 and ,80 
years; absence of pregnancy; absence of secondary causes 
of hypertension, such as renal artery stenosis; continu-
ous fulfillment of the conditions of resistant hyperten-
sion, which were stated to be blood pressure greater than 
140/90 mmHg on three antihypertensive medications and 
a diuretic (Table 7). When the 1,034 patients seen in their 
  Hypertension Clinic were reviewed, only 15 individuals 
(1.5%) met these criteria.71
The Symplicity Hypertension-2 (HTN) Trial68,72 meets 
these criteria, as far as we can tell. In 2010, the Symplicity 
Investigators, led by Murray Esler, reported a study72 that 
involved 106 subjects randomized to standard treatment 
(n = 54) versus standard treatment and radiofrequency renal 
nerve ablation (n = 52). Average blood pressure on three 
antihypertensive agents was 178/96 mmHg at baseline. At 
6 months, data were available on 51 of 54 control patients 
(94%) versus 49 of 52 denervation patients (94%). Blood 
pressure average was not different in the control group. The 
denervation group recorded a fall of 32/12 mmHg on aver-
age (P , 0.001). At 6 months, there were 18 of 51 control 
study subjects (35%), whose systolic pressure had fallen 
by 10 mmHg or more. At 6 months, there were 41 of 49 
denervation study subjects (84%) whose systolic pressure 
had fallen by 10 mmHg or more (P , 0.001). There were 
no serious side effects of the procedure.
In 2012, Hering et al published a series of patients with 
resistant hypertension complicated by Stages 3 to 4 chronic 
renal insufficiency. This study73 involved 15 study subjects 
with a baseline average blood pressure of 174/91 on an aver-
age of 5.6 antihypertensive medications. The mean creatinine 
clearance was 31 ± 9 mL/min, with a range of 15–43 mL/min. 
At the 12-month follow-up, there was no decrease in mean 
creatinine clearance. There were no serious side effects of the 
procedure. To our knowledge, this is the only longitudinal International Journal of Nephrology and Renovascular Disease 2013:6 submit your manuscript | www.dovepress.com
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report addressing the problem of preservation of renal 
function over time.
In 2012, Brinkmann et al published a report,74 involving 
twelve individuals with difficult-to-control hypertension. 
They were 45–74 years of age. Following radiofrequency 
ablation of their renal artery nerves, the mean blood pressure 
did not change from a baseline of 157 ± 7 → 157 ± 6 mmHg 
systolic; 95 ± 4 → 95 ± 4 mmHg diastolic. Three of the twelve 
patients did experience a significant fall in blood pressure. 
Heart rate did not change significantly: 61 ± 3 → 58 ± 2 per 
minute. Muscle sympathetic nerve activity did not change 
significantly: 34 ± 2 → 32 ± 3 bursts per minute. Clonidine 
was associated with a fall in blood pressure of 27 ± 0 mmHg 
systolic; 13 ± 5 mmHg diastolic with a decrease in muscle 
sympathetic nerve activity of 8 ± 1 bursts/minute – suggest-
ing these patients had the expected central sympathetic nerve 
activity increases seen in essential hypertension. But changes 
in blood pressure following renal denervation correlated with 
neither changes in muscle nerve sympathetic activity nor 
plasma norepinephrine concentration, placing doubt on the 
systemic effect of local denervation.
Long-term follow-up studies will be required to settle the 
question of cardiovascular benefit or risk related to ablation 
of renal artery sympathetic nerves and technologies that 
might be safely used to accomplish this end75,76 (Table 8). 
Currently, investigations of various radiofrequency strategies 
for ablation appear to be enrolling more subjects than those 
for cryoablative strategies. More invasive (laparoscopic) or 
less-invasive (ultrasonic) strategies can be expected. We will, 
however, need several more years of experience to clarify 
benefits, if any, their durability, and side effects in clinical 
research follow-up studies. At this point in time, it is too 
early to claim procedural success, based only upon lower 
office blood pressures. Payment for these procedures will 
not be forthcoming from insurance carriers without statisti-
cal demonstration of a decrease in cardiovascular events in 
the absence of serious side effects, despite efforts to design 
a set of guidelines.77
Future studies
Success rates for radiofrequency ablations have consistently 
been overestimated in initial scientific reports. In the real 
world, ablation of arrhythmogenic foci and nerve connections 
are often incomplete, impermanent, and require repeated 
efforts. Exuberant adoption of ablative procedures has 
Table 8 Pros and cons of radiofrequency ablation of renal artery 
sympathetic nerve endings
Pros
•    Decrease in problems of compliance and drug side effects
•    Long-term medication cost lower
•    Potential for reducing hard outcomes (suggested by degree of blood 
pressure lowering in short trials)
•    Potentially safe for chronic renal disease patients with $45 mL/min in 
whom antihypertensives are not working (Stage 3A or better)79
Cons
Absence of:
•    Accurate cardiovascular outcome data
•    Placebo or sham controlled studies
•    experience with patient groups listed under exclusions in Table 7
•    Consensus on trial of ganglionic blocking agents prior to ablation
•    Data on comparative cost of medications versus high-tech equipment 
(catheters, MRI, procedure)
Risks related to:
•    Radiation and contrast exposure
•    Potential for renovascular complications (perforation, dissection, 
atheroembolism, keloid, necrosis)74,75
•    Possibility of orthostatic symptoms
•    Potential for sympathetic renal dystrophy
Abbreviation: MRI, magnetic resonance imaging.
Table 7 Renal artery sympathetic radiofrequency ablation for 
resistant hypertension
Study inclusion criteria
•    Blood pressure greater than 140/90 both day and night while 
complying with three or more antihypertensive medications of which 
one is a diuretic
•    Between the ages of 18 and 80 years
•    Appropriate renal artery anatomy (single renal artery greater than 
4 mm diameter, .20 mm length to each kidney)75,76
Study exclusion criteria
Anatomic
•    Renal arterial anatomic exclusions (prior renal arterial intervention or 
evidence for renal artery stenosis, vessel smaller than 4 mm diameter, 
or ,20 mm length)
Related to systemic disease
•    Primary pulmonary hypertension
•    Chronic oxygen support or mechanical ventilation
•    Type 1 diabetes mellitus
•    Chronic kidney disease with eGFR ,45 mL/min or active focal 
sclerosis
•    MI, angina, CvA within 6 months
•    Prior history of autonomic dysfunction
Related to hypertension
•    Secondary forms of hypertension
•    Requirement for, or use of, medication or recreational substance 
known to raise blood pressure
Other
•    Pregnancy or plan for pregnancy
•    Prior keloid formation
•    ICD or pacemaker, or any other metallic implant not compatible with 
MRI
Abbreviations: eGFR, estimated glomerular filtration rate; MI, myocardial infarction; 
CvA,  cerebrovascular  accident;  ICD,  implantable  cardioverter-defibrillator;  MRI, 
magnetic resonance imaging.International Journal of Nephrology and Renovascular Disease 2013:6 submit your manuscript | www.dovepress.com
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demonstrated that procedural “success” may be overstated, 
and that soft endpoint reduction (of arrhythmia burden) may 
not lead to reduction of hard endpoints. Current studies of 
nonsurgical renal sympathetic ablation by any   modality78 
will need to learn from past observation. Durability of 
effect cannot be assumed from short-term studies, and per-
manence of effect may have unanticipated consequences 
(postcardiovascular or neurological event hypotension or 
autonomic dysfunction). To this point, the discomfort of 
renal sympathetic ablation has only been reported as a brief 
procedural consequence. Surgical regional sympathetic nerve 
ablation has been associated with regional side effects. We 
will have to be alert for the possible existence of renal sym-
pathetic dystrophic symptoms.
Though there are many drugs in the pipeline anticipated 
to lower blood pressure and to reduce cardiovascular and 
all cause mortality, there are few that have a primarily auto-
nomic target. Among those currently considered, side effect 
profiles have not permitted widespread use. Until drugs are 
developed that specifically target the sympathetic system, 
concentration on local peripheral sympathetic blockade is 
the most likely new tool to reduce cardiovascular and renal 
events. We should not consider one therapy as opposed to 
others, but rather what treatment strategies at our disposal 
produce the most long-term benefit with the least risk for 
patients with resistant hypertension.
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